التفاصيل البيبلوغرافية
| العنوان: |
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database. |
| المؤلفون: |
Malapelle, Umberto1 (AUTHOR), Passiglia, Francesco1,2 (AUTHOR), Pepe, Francesco1 (AUTHOR), Pisapia, Pasquale1 (AUTHOR), Lucia Reale, Maria3 (AUTHOR), Cortinovis, Diego4 (AUTHOR), Fraggetta, Filippo5 (AUTHOR), Galetta, Domenico6 (AUTHOR), Garbo, Edoardo2 (AUTHOR), Graziano, Paolo7 (AUTHOR), Pagni, Fabio8 (AUTHOR), Pasello, Giulia9 (AUTHOR), Piovano, Pierluigi10 (AUTHOR), Pilotto, Sara11 (AUTHOR), Tiseo, Marcello12 (AUTHOR), Genova, Carlo13,14 (AUTHOR), Righi, Luisella2 (AUTHOR), Troncone, Giancarlo1 (AUTHOR), Novello, Silvia1,2 (AUTHOR) silvia.novello@unito.it |
| المصدر: |
Lung Cancer (01695002). May2024, Vol. 191, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*NON-small-cell lung carcinoma, *DATABASES, *MEDICAL personnel, *BIOMARKERS, *MEDICAL records |
| مصطلحات جغرافية: |
NAPLES (Italy) |
| الشركة/الكيان: |
UNIVERSITA di Torino |
| مستخلص: |
• A plethora of predictive biomarkers have been approved by international societies for the clinical management of advanced NSCLC patients. • Scant diagnostic material and testing strategies (RT-PCR, NGS) drastically impacts on the molecular profiling of NSCLC patients. • Harmonized procedures are crucial to optimize pre-analytical, analytical and data reporting. • Biomarkers ATLAS (https://biomarkersatlas.comTest/) knowledge-based database is a diagnostic tool supporting healthcare personnel integrating updated clinical and molecular records from patients collected in 80 referral Italian institution. To date, precision medicine has revolutionized the clinical management of Non-Small Cell Lung Cancer (NSCLC). International societies approved a rapidly improved mandatory testing biomarkers panel for the clinical stratification of NSCLC patients, but harmonized procedures are required to optimize the diagnostic workflow. In this context a knowledge-based database (Biomarkers ATLAS, https://biomarkersatlas.comTest/) was developed by a supervising group of expert pathologists and thoracic oncologists collecting updated clinical and molecular records from about 80 referral Italian institutions. Here, we audit molecular and clinical data from n = 1100 NSCLC patients collected from January 2019 to December 2020. Clinical and molecular records from NSCLC patients were retrospectively collected from the two coordinating institutions (University of Turin and University of Naples). Molecular biomarkers (KRAS, EGFR, BRAF, ROS1, ALK, RET, NTRK, MET) and clinical data (sex, age, histological type, smoker status, PD-L1 expression, therapy) were collected and harmonized. Clinical and molecular data from 1100 (n = 552 mutated and n = 548 wild-type) NSCLC patients were systematized and annotated in the ATLAS knowledge-database. Molecular records from biomarkers testing were matched with main patients' clinical variables. Biomarkers ATLAS (https://biomarkersatlas.comTest/) represents a unique, easily managing, and reliable diagnostic tool aiming to integrate clinical records with molecular alterations of NSCLC patients in the real-word Italian scenario. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
